Allosteric Bioscience, Inc. Targets Extending Longevity




Allosteric Bioscience, Inc. Targets Extending Longevity

NEW YORK–(BUSINESS WIRE)–Allosteric Bioscience, Inc. is delineating the Molecular Mechanism of Aging and Longevity with the goal of optimizing the aging process and extending longevity. It is utilizing Genomics, Biology, Genetics, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular Technologies.

Select targets include Sarcopenia (muscle loss) prevention and treatment, Lamin A epigenetics, Tryptophan Metabolism, improved DNA repair, optimizing mitochondrial metabolism and control of factors comprising a Master Aging Complex identified by Dr. Arthur P. Bollon, who is President and Co-Founder of Allosteric Bioscience, Inc.

Dr. Bollon indicates that “Delineation of the Aging and Longevity Molecular Mechanism permits making modulators for key factors that will enhance the aging process, reduce aging related diseases and significantly extend longevity. We welcome inquires about our technologies and opportunities for collaboration and partnering”.

Contacts

Dr. Arthur P. Bollon, President and Co-Founder of Allosteric Bioscience, Inc., arthurb@flash.net, abollon@allostericbioscience.com, 469-585-7613.

Bruce Meyers, Executive Chairman and Co-Founder of Allosteric Bioscience, Inc., bmeyers@allostericbioscience.com, 469-391-7957.

www.allostericbioscience.com

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients




Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients

TORONTO–(BUSINESS WIRE)–#ARDS–Vasomune Therapeutics, Inc., (“Vasomune”), a clinical-stage biopharmaceutical company, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application to develop Pegevongitide (AV-001) for use in the acute resuscitation of severely burned patients. Pegevongitide, an injectable Tie2 agonist that blocks vascular leak, is currently being researched for the prevention and treatment of acute respiratory distress syndrome (ARDS) (NCT05123755).

“Vascular leak reflects a loss of endothelial barrier integrity, thereby allowing fluid and proteins to escape the intravascular space into surrounding tissues. This disrupts oxygen delivery, organ perfusion, and destabilizes hemodynamics. By activating the pivotal target Tie2, Pegevongitide targets a root mechanism of endothelial instability and leakage,” said Harold Kim, Ph.D., Vice-President of Research at Vasomune.

“In severely burned patients, vascular leak allows large volumes of fluid, proteins, and inflammatory mediators to shift from the bloodstream into injured and uninjured tissues,” said Dr. John C Kubasiak, Chief of Burn Surgery at Loyola University Medical Center in Chicago. “As a burn surgeon, I witness the impact of vascular leak driving profound edema, shock, impaired oxygen delivery, and multi-organ dysfunction.”

This new IND clearance allows Vasomune to initiate a clinical program evaluating Pegevongitide safety and efficacy in the resuscitation of severely burned patients. Pegevongitide offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. Published preclinical data using Pegevongitide supports that this mechanism can reduce vascular leak and improve hemodynamic function.

Dr. Ei Yamada, President & CEO of AnGes, said that “We are encouraged by the FDA decision to allow the expansion of our AV-001 development program. Our commitment to developing AV-001 will allow us to take a step forward in the treatment of serious pathologies driven by vascular leak.”

About Vasomune Therapeutics, Inc.

Vasomune Therapeutics, Inc. is a private clinical-stage biopharmaceutical company developing the next generation of medicines to boost the body’s ability to defend against vascular leak. Founded in 2014, Vasomune has focused on vascular normalization strategies, and has progressed the lead candidate Pegevongitide (AV-001) from bench to bedside. Vascular dysfunction and vascular leak are associated with the pathology of several disease states, including bacterial and viral pneumonia and acute respiratory distress syndrome, sepsis, hemorrhagic shock, acute kidney injury, stroke, and vascular dementia. Vasomune’s corporate headquarters and laboratories are in Toronto, Canada with US offices in Raleigh, NC. For more information about the company please visit http://www.vasomune.com.

About AnGes, Inc.

AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based medicines. The company’s flagship development product and genetic drug, HGF gene therapy products, received Breakthrough Therapy designation from the FDA in 2024. AnGes is currently working on the development of a Tie2 tyrosine kinase receptor agonist (AV-001) for viral and bacterial-associated pneumonia and an NF-κB decoy oligonucleotide for chronic discogenic lumbar back pain. Furthermore, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome-editing technologies. For more information, visit https://www.anges.co.jp/en/.

Contacts

Shahid Ahmad, Vice-President Operations and Planning

Vasomune Media Relations

sahmad@vasomune.com

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)




Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

An investigational medicine that addresses the genetic root cause of BAG3 DCM, AFTX-201 is being evaluated in the UPBEAT^© clinical trial

AFTX-201 is designed using Affinia’s proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids

WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for AFTX-201, a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated dilated cardiomyopathy (DCM).

AFTX-201 is designed to deliver a fully human, full-length BAG3 transgene using Affinia’s proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than those associated with gene therapies using conventional capsids such as AAV9 or AAVrh74. The safety and efficacy of AFTX-201 as a treatment for people living with BAG3 DCM is being investigated in the UPBEAT^© clinical trial. AFTX-201 is given as a simple one-time intravenous administration. Preclinical studies in an animal disease model demonstrated that AFTX-201 increased BAG3 protein levels in the heart and completely restored cardiac function.

“We are grateful to the FDA for granting the Fast Track designation to AFTX-201 as a treatment for BAG3 DCM and to the patient and physician communities for their support of our UPBEAT clinical trial,” said Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia. “This Fast Track designation, together with the FDA’s recent approval of our IND application for AFTX-201 and the European Medicines Agency’s designation of AFTX-201 as an Orphan Drug, strengthens our conviction that AFTX-201 has the potential to significantly improve the lives of those affected by BAG3 DCM.”

“DCM is the leading cause of heart failure in young people and the most frequent indication for heart transplantation despite current treatments,” said Greg Ruf, Founder and Executive Director of the DCM Foundation. “People whose DCM is caused by a genetic mutation such as BAG3 may benefit from a gene therapy approach.”

Fast Track designation is designed to help drugs reach patients faster based on the drug’s potential to fill an unmet medical need and treat serious conditions. Programs receiving FTD benefit from early and frequent interactions with the FDA during the clinical development process and review of the marketing application on a rolling basis before the sponsor submits the complete application. If relevant criteria are met, the FDA may also consider an accelerated approval and priority review of the marketing application. These benefits could decrease the development time of the drug to approval.

About the UPBEAT^© clinical trial

The UPBEAT clinical trial (NCT07426419 on clinicaltrials.gov) is a multicenter, single-arm, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The trial includes a dose-exploration phase followed by a dose-expansion phase. All participants will receive a single intravenous infusion of AFTX-201 at a dose that has been deemed safe and efficacious based on preclinical studies. The primary objective of the trial is to evaluate safety and tolerability through 52 weeks following administration. Secondary and exploratory objectives include pharmacodynamic and preliminary efficacy assessments, which will be evaluated as changes from baseline. Study design, dose selection, and monitoring plans are informed by input from patients, clinicians, and regulators and by completed nonclinical proof-of-concept, biodistribution, and safety studies, which demonstrated complete correction of heart ejection fraction to normal (wild-type) level and adequate safety margin for the doses being explored in the clinical trial. Protocol-defined stopping rules, centralized safety data review, and oversight by an independent Data Safety Monitoring Board are implemented to ensure the safety of participants. Interested participants are encouraged to reach out to Affinia via clinicaltrials@affiniatx.com and to their medical care provider.

About Affinia Therapeutics

Affinia Therapeutics is a clinical-stage biotech company pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates, initially in cardiovascular diseases, leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models. For more information, visit https://www.affiniatx.com.

Contacts

Media contact:
Kathy Vincent

kathy@kathyvincent.com
310-403-8951

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America




Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

• Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing Shield blood test directly to Americans
• Route will focus on rural communities across the country with the lowest screening rates and highest CRC incidence and mortality
• Shield is proven to increase screening rates with a 93% adherence

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and recommended in national guidelines, directly to over 100 communities across the country from Las Vegas to Hartford, Atlanta and more.

From national sporting events to rural senior centers and beyond, the tour will educate patients on the importance of CRC screening and provide patients of screening-eligible age the opportunity to screen with Shield via the mobile screening lab. The Shield Across America tour will focus on rural areas that face the biggest barriers to colorectal cancer screening and the highest incidence and mortality rates.

The tour launch coincides with National CRC Awareness Month, underscoring Guardant Health’s commitment to close America’s colorectal cancer screening gap and help more Americans get screened.

CRC remains the second leading cause of cancer-related deaths in the U.S., and recently the leading cancer death for those under 50. Despite being highly treatable when caught early, more than 54 million eligible Americans – 1 in 3 – do not complete their CRC screening because they find current options unpleasant or inconvenient. Shield Across America aims to eliminate the barriers that have kept many Americans from getting screened by expanding access to Shield through mobile screening lab stops nationwide.

“Shield Across America seeks to address a fundamental challenge in colorectal cancer screening in our country: access,” said AmirAli Talasaz, Guardant Health co-CEO. “By bringing screening directly to where Americans live, work and enjoy with a focus on our rural communities who face some of the biggest barriers to screening, we aim to encourage more people to get their lifesaving screening and close our nation’s screening gap.”

Shield is proven to increase screening rates in the real world, with 93% of patients completing the test in the first 100,000 Shield tests ordered – a significant improvement in screening adherence rates over other types of tests.¹ Recently, the National Comprehensive Cancer Network included the Shield blood test in its updated CRC screening guidelines, paving the way for improved patient access and additional major clinical guideline inclusions.

Built on Guardant’s proprietary technology pioneered more than a decade ago, Shield is covered by Medicare, the Veterans Affairs Community Care Network and TRICARE, for active-duty service members, and is commercially available across the U.S.

Shield is available by prescription only and can be completed during a routine doctor’s visit. To find a screening event near you or find more details on the Shield test to discuss with your local provider, visit ShieldAcrossAmerica.com.

About Shield

Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

¹ Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582.

Contacts

Investor Contact:
Zarak Khurshid

investors@guardanthealth.com

Media Contact:
Meaghan Smith

press@guardanthealth.com

Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions




Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions

Extension financing adds new investors, Janus Henderson Investors and RA Capital, with strong renewed participation from existing investors

Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions

Phase 1 clinical trial for PHB-050 remains on track

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Poplar Therapeutics, Inc., a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions, today announced the closing of its Series A extension round, bringing its total Series A financing to $95 million. The round was led by Janus Henderson Investors, with RA Capital also participating as a new investor. The financing was further supported by existing investors, including SR One, Vida Ventures and affiliates of ArrowMark Partners. The additional capital from this financing will support the continued advancement of its lead asset, PHB-050, through clinical development.

“Poplar Therapeutics is advancing a differentiated approach that has the potential to redefine how IgE-mediated diseases are treated,” said Daniel Lyons, PhD, CFA, Portfolio Manager, Research Analyst, Janus Henderson Investors. “We believe the upcoming Phase 1 data will be an important milestone in validating this novel mechanism and we look forward to supporting the company as it works to bring this therapy to patients in need.”

PHB-050 is currently in a Phase 1 clinical trial for food allergy. The ongoing trial is expected to generate key data on safety, pharmacokinetics and the potential to rapidly reduce circulating IgE levels toward zero, which could inform the next stage of clinical development.

“This extension reflects the strong conviction of our new and existing investors in Poplar’s differentiated science and clinical strategy and will allow us to continue the development of our potential best-in-class anti-IgE therapy through Phase 2 clinical trials,” said Chip Baird, chief executive officer of Poplar Therapeutics. “We are thrilled to have Janus and RA Capital join our exceptional investor partners in our shared goal of transforming the treatment of atopic disease. We believe that PHB-050 has the potential to help millions of patients in need of effective treatment options.”

Despite the availability of omalizumab (Xolair®), a first-generation anti-IgE therapy, millions of patients with atopic diseases such as food allergy, allergic asthma and atopic dermatitis lack effective treatment options, representing a significant unmet medical need. Patients with elevated IgE levels are ineligible for or do not adequately respond to currently available treatments.

About PHB-050

More than seven million patients with atopic conditions have high IgE levels, with approximately three million considered ineligible for or resistant to current standard therapies. In food allergy, approximately 50% of patients are classified as having high IgE levels.

PHB-050 is a novel, next-generation anti-IgE antibody designed to treat multiple atopic diseases, including food allergy, asthma and atopic dermatitis with potential application for select orphan immunology and inflammatory diseases. Its unique triple-action mechanism is designed to not only block IgE from binding to mast cells that trigger allergic reactions, but also to rapidly reduce circulating IgE and inhibit its production.

About Poplar Therapeutics

Poplar Therapeutics, Inc. is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in treating allergic disorders, which was incorporated in 2024. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.

Contacts

Media Contact:

Terri Clevenger

tclevenger@waterhousebrands.com

Sanaregen™ Vision Therapeutics Receives FDA Clearance for Clinical Trial to Treat Retinal Degeneration




Sanaregen™ Vision Therapeutics Receives FDA Clearance for Clinical Trial to Treat Retinal Degeneration

NASHVILLE, Tenn.–(BUSINESS WIRE)–#ClinicalTrials–Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, today announced clearance by the U.S. Food and Drug Administration to conduct a Phase I/II clinical trial for SVT-001, its investigational cell therapy.

The trial will assess safety and effectiveness of SVT-001 to improve retinal function and restore vision in individuals with Familial Drusen, an inherited form of macular degeneration. There are currently no approved disease-modifying treatments for the condition.

“This is a pivotal moment not only for our company, but for the families that have endured generations of early-onset blindness,” said Anthony Oliva, Ph.D., Chief Scientific Officer and co-founder. “We believe SVT-001 provides true hope to prevent the almost inevitable vision loss caused by this devastating condition that has largely been overlooked.”

Doug Oliver, President and co-founder, reflects on forwarding SVT-001 into clinical trials. “This represents nearly a decade of advocacy, scientific groundwork, regulatory cooperation and mission focus.” Oliver, a global award-winning patient advocate who has Familial Drusen, is known for his personal experience of vision recovery following cell-based therapy, which fueled his work with lawmakers to craft the 21^st Century Cures Act. “I believe this cell therapy will ultimately be proven safe, easily administered, and highly effective at preventing and reversing vision loss. It’s a very exciting time for our company and patients alike.”

Rare Disease with Broader Market Implications

Familial Drusen is an aggressive retinal degeneration disorder characterized by early-age accumulation of waxy pathological deposits beneath the retina, called drusen. Many affected patients begin experiencing progressive central blindness around 40 years of age. While distinct from the much more prevalent disorder, dry age-related macular degeneration (AMD), the pathological similarities, including drusen accumulation and geographic atrophy, positions SVT-001 as a promising therapeutic candidate for AMD.

About Sanaregen Vision Therapeutics, Inc.

Sanaregen Vision Therapeutics is a U.S.-based biopharma company committed to developing affordable, accessible, and innovative cell-based therapies for degenerative retinal diseases.

Forward-Looking Statements

This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially. We undertake no obligation to update this information, which speaks only as of this date, except as required by law.

Contacts

Media Contact:
Kristen Hayner

KH Strategic Communications

kristen@kristenhayner.com

Investment Inquiries:
invest@sanaregenvision.com
sanaregenvision.com/invest

Patient Inquiries:
sighttrial@sanaregenvision.com
+1 615.369.3576

BioTalent Canada Breaks Barriers in Opening Applications for 2026 I.D.E.A.L. Scholarship™




BioTalent Canada Breaks Barriers in Opening Applications for 2026 I.D.E.A.L. Scholarship™

OTTAWA, Ontario–(BUSINESS WIRE)–#ait–BioTalent Canada has opened applications for the third annual I.D.E.A.L. Scholarship which will close on June 8, 2026. Full details and application forms available on BioTalent Canada’s website.

Breaking down financial barriers today will shape the discoveries and therapies we all rely on tomorrow. For many aspiring scientists and innovators, it is financial barriers which stand in the way of ambition and opportunity. To combat this, BioTalent Canada is once again accepting applications for the 2026 I.D.E.A.L. Scholarship™, a national scholarship that helps remove barriers and expand inclusion in Canada’s bio-economy, now in its third year.

Three scholarships of $10,000 each will be awarded to students entering their first year of an accredited bioscience-related program at a Canadian college, university, or CEGEP who have demonstrated leadership and a commitment to inclusion, diversity, equity and accessibility. Eligible applicants include Indigenous students, persons with disabilities and newcomers to Canada.

“Inclusion ensures Canada’s bio-economy can thrive, powered by the ideas, perspectives and talent of all communities, including ones that are often left on the sidelines,” says Rob Henderson, President and CEO, BioTalent Canada. “Through the I.D.E.A.L. Scholarship, we are reaching underrepresented students entering their first year of a post-secondary bioscience program from across Canada so they can access education, build skills and bring their unique ideas to the labs, clinics and companies shaping our future.”

BioTalent Canada, a national leader in bio-economy labour market intelligence and skills development, created the I.D.E.A.L. Scholarship™ to increase participation from underrepresented communities in Canada’s growing bio-economy by reducing financial barriers for first-year students and opening doors to meaningful careers across the country.

“This scholarship fueled my mission to turn my own challenges into opportunities for others,” said Gayoung Park, a 2025 I.D.E.A.L. Scholarship recipient. “It’s not enough to invite people in. Real inclusion ensures they feel they belong.”

Students, educators and community organizations are encouraged to visit the I.D.E.A.L. Scholarship webpage and share this opportunity with eligible learners who aspire to build a career in Canada’s bio-economy.

To learn more about eligibility and apply, visit biotalent.ca/IDEALscholarship or contact Soufiane at info@biotalent.ca.

Rob Henderson is available for comment.

About BioTalent Canada

BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy contributors with evidence-based data and industry-driven standards. BioTalent Canada, as a workforce development council, is focused on igniting the industry’s brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada’s most vital sectors.

BioTalent Canada has received varied distinctions following a thorough and independent analysis of the organization. By practicing the same industry standards it recommends to partners, the organization has been honoured with the following titles:

• Great Place to Work^® since 2019 and one of the Best Workplaces in Healthcare for 2023 by Great Place to Work Canada^®
• The Best Leader in Diversity, Equity, and Inclusion at the 2024 Best Ottawa Business Awards
• 2024 Collaboration Catalyst by Magnet Network
• One of Canada’s Best Places to Work by HRD Canada for 2024
• 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter since 2023
• Employer of Choice by Canadian HR Reporter for 2025

For more information, visit biotalent.ca.

About I.D.E.A.L. Scholarship™:

The I.D.E.A.L. Scholarship aims to promote inclusion, diversity, equity and accessibility leadership (IDEAL) within the realm of biosciences. Designed to inspire and support equity-deserving groups in embarking on their bioscience journeys, this program not only seeks to diversify Canada’s bio-economy but also to amplify enrollment in biosciences programs nationwide. Through targeted support and a commitment to fostering a culture of inclusivity and innovation, the I.D.E.A.L. Scholarship promises to empower and uplift individuals from diverse backgrounds, thereby driving the future of biotechnology in Canada forward.

Contacts

Media Contact:
Eli Duern

Project Manager, Marketing and Communications

BioTalent Canada

613-235-1402 ext. 225

eduern@biotalent.ca

Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance




Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance

NEUCHÂTEL, Switzerland–(BUSINESS WIRE)–#CataractSurgery–Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery. Unlike traditional Extended Depth of Focus lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL – while preserving contrast sensitivity, visual quality, and minimizing side effects such as halos and glare, hallmarks of its patented fully refractive design.

A recent peer-reviewed study, Comparative Analysis of Visual Outcomes Between Lucidis 108M (EDOF) and PhysIOL BVI FineVision (Diffractive) IOLs Using Defocus Curve Measurements by H. Naftali, W. Nasser, and M. Naftali, provides compelling comparative data. The findings show that Lucidis® achieves a defocus curve remarkably close to that of a leading diffractive trifocal, demonstrating excellent distance, intermediate, and functional near vision. These results validate the unique optical concept behind Lucidis®, which combines a spherical monofocal base with the Instant Focus™ refractive element, engineered to extend the depth of focus and significantly reduce dysphotopsia.

Beyond the clinical outcomes highlighted in the Naftali study, the functional classification research led by Joaquin Fernandez, PhD, further positions Lucidis® distinctively within the category of full-range IOLs (FRoF). According to this work, Lucidis® provides consistent visual acuity at all distances – supporting surgeons seeking a premium solution that delivers high spectacle independence with high patient satisfaction.

Lucidis® is engineered and manufactured in Switzerland according to the highest precision standards. Its refractive design offers an alternative to multifocal technologies for patients who demand performance without compromise. With its mechanical stability in the capsular bag and consistently predictable refractive outcomes, Lucidis® is increasingly recognized as a premium reference in international markets.

“As the demand for spectacle independence grows, the need for advanced, reliable, and well-tolerated solutions becomes essential,” says Swiss Advanced Vision. “Lucidis® empowers surgeons to offer their patients a premium experience with confidence—full-range vision, visual quality, and an exceptional safety profile.”

If you’re an eyecare professional looking to save time and gain further clinical insights, now’s the perfect moment to join the Swiss Virtual Clinic on sav-iol.com!

Since 2009, SAV-IOL develops and markets advanced EDOF IOLs globally. Its LUCIDIS and EDEN lenses, powered by Instant Focus technology, provide continuous vision from near to intermediate and far distances.

Contacts

Tel. +41 32 566 54 00 // info@sav-iol.com

Dxcover Secures CE-IVDR Certification




Dxcover Secures CE-IVDR Certification

Key Milestone Signals Readiness for Regulated Diagnostic Deployment

GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover, a global leader in AI-enabled technologies, today announced that its breakthrough liquid biopsy medical device has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.

“This validates not just a single product, but the underlying rigor of our infrastructure — from software architecture and data pipelines to clinical evidence and quality processes,” said Matthew Baker PhD, CEO & co-Founder, Dxcover. “It de-risks Dxcover’s ability to scale its technology across multiple clinical applications, an important step in furthering Dxcover’s mission to detect cancer early and benefit patients.”

Dxcover now becomes one of the bold leaders leveraging AI and machine-learning into its IVDR-compliant Class C medical device software. CE-mark for a Class C device is granted to diagnostic devices delivering results that are highly significant for patient care and treatment decisions. Achieving CE-IVDR Class C status reflects compliance with one of the most stringent regulatory standards in Europe.

“Dxcover’s technology represents a step-change in diagnostic approach. But disruptive innovation can only be realized in practice when subject to the highest levels of regulatory scrutiny, which is why we are delighted to have reached this milestone,” added David Eustace PhD, General Manager, Dxcover. “This high impact certification provides the most solid of regulatory foundations to support commercialization and future growth.”

About Dxcover

Dxcover is changing how early, how accurately, and how efficiently cancer can be detected. The company’s platform integrates infrared spectroscopy data with proprietary algorithms to support earlier and more actionable clinical insights from a small amount of blood, yielding results in hours instead of weeks. AI-powered insight, delivered at light speed.

Further Information: https://www.dxcover.com/

Contacts

Media Contact: info@dxcover.com

Linnea Achieves CEP Certification for Cannabidiol Isolate




Linnea Achieves CEP Certification for Cannabidiol Isolate

RIAZZINO, Switzerland–(BUSINESS WIRE)–#CEP—Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP).

The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe.

Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required.

This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with assurance regarding product quality, regulatory compliance, and manufacturing expertise.

“This achievement reflects our unwavering focus on quality, transparency, and regulatory excellence,” said Giorgia Tossi, Chief Quality Officer – Technical Responsible/QP. “We are grateful to our teams whose dedication made this milestone possible, and to our customers who continue to place their trust in us.”

With this certification, Linnea strengthens its position as a trusted supplier of premium cannabinoid ingredients and continues its journey towards enhanced global compliance and quality leadership.

ABOUT LINNEA

Founded in 1982, Linnea is a Swiss-based manufacturer of premium botanical active ingredients for the pharmaceutical, nutraceutical, and cosmetic industries. Operating from a GMP-certified facility, the company is also a leader in medical cannabinoids, applying a pharma-driven, approach to cannabinoid development. Serving over 300 clients in more than 50 countries, Linnea combines regulatory expertise, scientific excellence, and tailored support to deliver high-quality, compliant solutions worldwide.

www.linnea.ch
www.linneacannabinoids.ch

Contacts

For more information, please contact:

Daniela Guerriero

Marketing & Communications Manager

Phone +41.91.850 5050

dguerriero@linnea.ch